TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Nutrition Status, BMD, and SSRIs

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Included adult NHANES participants are those who participated in the Dual-Energy X-ray Absorptiometry (DXA) femur-neck BMD test and responded in full to the demographic, pharmaceutical, and dietary surveys.~Exclusion Criteria:~* Pregnancy, incomplete survey responses, incomplete DXA results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- SSRI long-term user (Type: None): Adults, 655 with an SSRI prescription ≥180 days and identified in the National Health and Nutrition Examination Survey (NHANES) data.
- Non-user (Type: None): Adults, 12,372 non-users, were identified in the National Health and Nutrition Examination Survey (NHANES) data.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Asimadoline for the Treatment of Post-Operative Ileus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females aged 18-80~* Must be scheduled to undergo a laparoscopic/hand-assisted laparoscopic segmental colectomy~* Must sign an ICF~* Females of childbearing potential must have a negative pregnancy test at screening~Exclusion Criteria:~* Subjects with evidence of a biochemical or structural abnormality of the GI tract or other co-morbid illness that may impact the ability to interpret the safety and efficacy data~* Pregnant or breastfeeding females~* Use of investigational drugs in previous 30 days~* Refusal to discontinue prohibited concomitant medications~* Chronic use of prescription narcotics over the previous 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Asimadoline 1.0 mg (Type: ACTIVE_COMPARATOR): Asimadoline 1.0 mg b.i.d.
- Asimadoline 3.0 mg (Type: ACTIVE_COMPARATOR): Asimadoline 3.0 mg b.i.d.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated With Systemic Antibiotics

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Neonates and infants ≤3 months, with gestational age ≥28 weeks~* Documented or presumed (or at risk of) bacterial infections, and currently receiving antibiotic treatment~* Expected to survive beyond the first 7 days after enrollment~* Sufficient vascular access to receive study drug, and to allow blood sampling at a site separate from the study drug infusion site~* Parent's / legally acceptable representative's informed consent to participate in the study~Exclusion Criteria:~* Major birth defect or malformation syndrome~* Proven presence of an immunodeficiency~* HIV or other congenital viral or fungal infection~* Significant laboratory abnormalities including: hematocrit \<20%; absolute neutrophil count \<0.5x10⁹/L; platelet count \< 50x10⁹/L; alanine aminotransferase or aspartate aminotransferase \>3 times the age-specific upper limit of normal~* Impaired renal function or known significant renal disease~* Any condition which would make the subject or caregiver, in the opinion of the investigator, unsuitable for the study

- Gender: ALL
- Minimum Age: None
- Maximum Age: 3 Months
- Healthy Volunteers: f

Study Arms:
- Ceftobiprole (Type: EXPERIMENTAL): Ceftobiprole medocaril is the water-soluble prodrug of ceftobiprole, an advanced-generation cephalosporin developed for intravenous administration. Ceftobiprole is characterized by potent, broad-spectrum antimicrobial activity against both Gram-positive and Gram-negative pathogens.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Anti-Xa Activity of Enoxaparin for Prevention of Venous Thromboembolism in Severe Nephrotic Syndrome.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Severe NS, defined as proteinuria exceeding 3.5 g/24h or 50 mg/kg/24h and serum albumin ≤2.5 g/dL;~* eGFR ≥30 mL/min/1.73 m2.~Exclusion Criteria:~* Body mass index (BMI) ≥40 kg/m2;~* Low body mass (\<45 kg for female, \<57 kg for male);~* Acute VTE;~* Previously introduced anticoagulation (due to comorbidities);~* Contraindications for enoxaparin;~* Pregnancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Nephrotic syndrome - fixed dose (NS-FD) (Type: EXPERIMENTAL): Drug: Enoxaparin; Dose: 40 mg; Administration: once daily subcutaneously.
- Nephrotic syndrome - adjusted dose (NS-AD) (Type: EXPERIMENTAL): Drug: Enoxaparin; Dose: 1 mg/kg of ideal body weight; Administration: once daily subcutaneously.
- Control - fixed dose (C-FD) (Type: ACTIVE_COMPARATOR): Drug: Enoxaparin; Dose: 40 mg; Administration: once daily subcutaneously.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Vitamin K1 to Slow Progression of Vascular Calcification in HD Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or Female minimum 18 years of age~* Not less than 6 months on hemodialysis~* Cardiovascular calcification percent (coronary artery volume score \> 100)~* Written consent to take part in the study~* Life expectancy not less than 18 months~Exclusion Criteria:~* Known hypersensitivity against Vitamin K1~* History of thrombosis~* intake of Vitamin K~* tumor disease~* pulse \>100/min (resting heart rate)~* Intake of vitamin K antagonists (e.g. Marcumar) at baseline or in the 3 months prior to baseline~* Inflammatory bowel disease~* Short-bowel syndrome~* Significant liver dysfunction~* more than one stent in one coronary artery plus one or more stents in an additional artery~* Hemoglobin \< 70 g/L~* Women who are pregnant or breastfeeding~* Women without sufficient contraception~* Alcohol or drug abuse~* Mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study~* Subject unlikely to comply with protocol, e.g. uncooperative attitude, inability to return for follow-up-visits and unlikelihood of completing the study~* Participation in a parallel clinical trial or participation in another clinical trial within the previous 3 months~* Subjects who are in any state of dependency to the sponsor or the investigators~* Employees of the sponsor or the investigators~* Subjects who have been committed to an institution by legal or regulatory order

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- standard treatment (usual care) (Type: NO_INTERVENTION): standard treatment (usual care)
- Vitamin K1 (Type: EXPERIMENTAL): Vitamin K1 (phylloquinone), thrice weekly p.o. (5mg)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Amniotic Fluid Tandem Mass Spectrometry for Pregnancies Complicated by NIH and Severe Symmetrical IUGR

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
NIH Inclusion Criteria:~* Singleton gestation~* 18 years of age or older~* Excess extracellular fluid in at least two fetal sites as noted by ultrasound: abdomen (ascites), the chest (pleural and pericardial effusions), the skin (edema \> 5mm), the amniotic cavity (polyhydramnios), and the placenta (thickening \> 6cm)~* NIH diagnosis \> 15w0d gestation~* Diagnostic amniocentesis performed at \> 15w0d gestation~NIH Exclusion Criteria:~* Immune-mediated hydrops fetalis as diagnosed by maternal red cell antigens and fetal anemia suspected by middle cerebral artery doppler ultrasound and/or confirmed by percutaneous umbilical blood sampling~* Structural anomaly identified by ultrasound~* Chromosomal aneuploidy~* Multiple gestations~IUGR Inclusion Criteria:~* Singleton gestation~* 18 years of age or older~* Severe symmetrical IUGR defined as a \> 3 week lag of all fetal ultrasound measurements (biparietal diameter, head circumference, abdominal circumference, and femur length)~* IUGR diagnosis between 24-32 weeks gestation~* Diagnostic amniocentesis performed prior to 32 weeks gestation~IUGR Exclusion Criteria:~* Asymmetrical IUGR~* Structural anomaly identified by ultrasound~* Chromosomal aneuploidy~* Multiple gestations

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- NIH/SSIUGR fetuses (Type: None): Group 1 includes pregnancies complicated by a fetus with either Non-Immune Hydrops or Severe Symmetrical IUGR.
- Control-Normal fetus (Type: None): Group 2 includes all normally appearing fetuses on U/S who will be having a diagnostic amniocentesis as part of their routine care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Respiratory Depression When Using a Hydromorphone Pain Protocol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Any patient who presents a condition that causes moderate to severe pain, according to the attending physician's judgment, in which the physician would order the use of parenteral analgesia~2. Able to provide consent.~Exclusion Criteria:~1. Patient or family member unable to consent~2. Altered mental status~3. SpO2 less than 95 percent~4. Allergy to opiates~5. Hypotension (Systolic blood pressure less than 90 mmHg)~6. Chronic oxygen dependency or known CO2 retention~7. Acute ETOH or drug intoxication~8. History of chronic pain syndrome or chronic use of opiate narcotics~9. History of opiate/heroin addiction, past or current.~10. End stage renal disease/dialysis patient~11. Chronic metabolic acidosis~12. Physician feels that patient would be poor candidate for study~13. Weight less than 100 pounds, all patients will be weighted~14. Patients younger than 60 years of age

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- 1mg + 1mg Hydromorphone (Type: ACTIVE_COMPARATOR): Patient will receive 1 mg of hydromorphone for pain at timepoint 0. After 15 minutes, patients will be asked if the still need pain medication. If yes, patients will immediately receive 1mg hydromorphone. Patients will be under continuous monitoring for respiratory depression via capnometer. At 60 minutes, pain will be re-assessed for a second time. If needed, physician will give additional pain meds per their discretion.
- Usual Care Group (Type: ACTIVE_COMPARATOR): Patient will receive pain medicine per doctor's discretion at timepoint 0. After 15 minutes, patients will be asked if they still need pain medication. If yes, physicians will not be notified and patient will continue to have pain managed as deemed necessary by physician per usual care. Patients will be under continuous monitoring for respiratory depression via capnometer. At 60 minutes, pain will be re-assessed for a second time. If needed, physician will give additional pain meds per their discretion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Allosure in Simultaneous Pancreas Kidney Transplant

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years~* Kidney-pancreas transplant recipients~* Patient must have stable creatine, lipase, amylase for at least a two month span after transplant OR patient must receive a biopsy within one year post transplant~Exclusion Criteria:~* Presence of non-renal or pancreas transplanted organ~* Patient is not enrolled within 1 year after transplant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- WU/Barnes cohort (Type: None): SPK patients in this group will be recruited from WU/Barnes Transplant center. A total of 25 from this cohort will be recruited and asked to provide a blood sample to test for donor derived cell free DNA 3 times over the course of the first year of transplant. In addition, if any biopsies or rejections occur, additional samples will be requested at the time of biopsy and for an additional two follow-ups at least one month apart.
- UT Southwestern cohort (Type: None): SPK patients in this group will be recruited from WU/Barnes Transplant center. A total of 25 from this cohort will be recruited and asked to provide a blood sample to test for donor derived cell free DNA 3 times over the course of the first year of transplant. In addition, if any biopsies or rejections occur, additional samples will be requested at the time of biopsy and for an additional two follow-ups at least one month apart.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Hearing and Balance Disorders in Peripheral Neuropathy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Individuals diagnosed with Charcot-Marie Tooth~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pediatric participants, 12 to 17 years of age inclusive~* Histologically confirmed surgically incurable and unresectable Stage IIIC or Stage IV (AJCC) melanoma~* Positive proto-oncogene B-Raf (BRAF) mutation result (Cobas 4800 BRAF V600 Mutation Test)~* Measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria~* Performance status: Karnofsky (for participants \>/= 16 years of age) or Lansky (for participants \< 16 years of age) score of \>/= 60~* Adequate bone marrow, liver and renal function~* Participants must have fully recovered from the acute toxic effects of all prior therapy prior to first administration of study drug~Exclusion Criteria:~* Active or untreated central nervous system (CNS) lesions~* History of or known spinal cord compression or carcinomatous meningitis~* Anticipated or ongoing administration of anti-cancer therapies other than those administered in this study~* Previous malignancy within the past 5 years except for basal or squamous cell carcinoma of the skin, melanoma in-situ, and carcinoma in-situ of the cervix~* Previous treatment with selective/specific BRAF or Methyl Ethyl Ketone (MEK) inhibitor (previous treatment with sorafenib is allowed)~* Any previous treatment with study drug (RO5185426) or participation in a clinical trial that includes RO5185426~* Pregnant or lactating females~* Known human immunodeficiency virus (HIV) positivity or acquired immune deficiency syndrome (AIDS)-related illness, active hepatitis B virus, or active hepatitis C virus

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Vemurafenib (Type: EXPERIMENTAL): Participants received vemurafenib into two separate cohorts with different starting doses based on greater than or equal to (\>=)45 kilogram (kg) and other weighing less than (\<)45 kg. The starting dose for participants (\>=45 kg) was 720 milligram (mg) of vemurafenib by mouth twice daily (BID) and the next dose level for participants in this cohort was 960 mg by mouth BID. The starting dose level for participants weighing \<45 kg was to be 480 mg of vemurafenib by mouth BID, but no participants were enrolled into this cohort.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Total vs. Reverse Shoulder Replacement: Pain Relief Two Years After Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 70 or older,~* have radiographic signs of osteoarthritis (narrowing of the glenohumeral joint space, marginal osteophytes around the humeral head, progressive changes with sclerosis and subcortical cystic formation and flattening of the humeral head),~* intact rotator cuff but with atrophy or fatty degeneration (defined as Grade II atrophy noted on preoperative shoulder ultrasound),~* objective weakness as measured with Isobex testing,~* limited forward elevation (less than 90 degrees)~Exclusion Criteria:~* patients who present with pain secondary to inflammatory arthropathy,~* obvious full-thickness rotator cuff tear,~* cuff tear arthropathy,~* revision arthroplasty,~* fracture or trauma,~* patients who had previous rotator cuff repair or prior open surgery prior to shoulder arthroplasty.~* pregnancy

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- Reverse Shoulder Arthroplasty (Type: ACTIVE_COMPARATOR): Shoulder Joint Replacement Reverse Arthroplasty Implant to surgically replace arthritic shoulder
- Total Shoulder Arthroplasty (Type: ACTIVE_COMPARATOR): Shoulder Joint Replacement Total Arthroplasty Implant used to surgically replace osteoarthritic shoulder joint

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of a Full-Thickness Placental Allograft in Lumbar Microdiscectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ambulatory with radiating low back and leg pain for greater than 6 months prior to surgery with clinical diagnosis of lumbar protruding disc.~* Consent and compliance with all aspects of the study protocol, methods, providing data during follow-up contact.~Exclusion Criteria:~* Severe hypertension systolic blood pressure (greater than or equal to 200 mm -Hg or diastolic blood pressure greater than or equal to 182 mm Hg)~* BMI greater than 45 kg/m2~* Subject has had major surgery at the index level~* Is an active smoker or stopped smoking in the last 6 months~* Any pain that could interfere with the assessment of index level pain (e.g. pain in any other part of the spine)~* Active rheumatoid arthritis~* Active, local or systemic malignancy such as lung cancer or leukemia~* History of vascular disease or sickle cell anemia~* Use of the following medications:~No significant anticoagulant therapy (e.g. Heparin or Lovenox) during the study (treatment such as Aspirin and Plavix are allowed)~* No systemic treatments that may interfere with safety or efficacy assessments during the study~* No immunosuppressants~* No use of corticosteroids~  * Subject is pregnant or plans to become pregnant within 24 months of treatment~ * Subject does not provide full consent~ * Personal injury, workman's compensation or other legally-related treatment patients.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Treatment (Type: EXPERIMENTAL): 91 patients will undergo a typical lumbar microdiscectomy with the addition of a full-thickness placental allograft after the microdiscectomy has been performed.
- Control (Type: NO_INTERVENTION): 91 patients will undergo a typical lumbar microdiscectomy without the addition of a full-thickness placental allograft.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues